How the UK 2026 Merger‑control Reforms Will Affect Private‑equity Backed M&A and Deal Financing

On 20 January 2026 the UK Department for Business and Trade (DBT) opened a consultation titled Refining our competition regime, proposing legislative changes that could reshape how private‑equity sponsors, lenders and general counsel approach UK deal‑making. Running in parallel, the Competition and Markets Authority (CMA) has updated its own merger guidance and launched a review of its approach to merger efficiencies under the banner of the “4Ps”, Pace, Predictability, Proportionality and Process. For mid‑market private‑equity backed transactions and the financing that underpins them, the UK merger control reforms 2026 create a materially different risk landscape, one that demands changes to deal documentation, timing assumptions, financing conditionality and intercreditor arrangements well before any new statute reaches the books.

This guide sets out the practical implications and provides actionable checklists for every party around the deal table.

Executive Summary, What Readers Must Know Right Now

The convergence of government consultation and CMA procedural reform in 2026 creates a compressed period of regulatory uncertainty for UK M&A. Sponsors and lenders who wait for final legislation risk being caught by interim CMA practice changes that are already taking effect. Below is a concise summary of what is changing, who is affected, and the immediate actions that deal teams should prioritise.

The DBT consultation, published on 20 January 2026, proposes clarifying jurisdictional scope, refining notification thresholds and streamlining CMA decision‑making and remedies. The CMA’s own updated Mergers: Guidance on the CMA’s jurisdiction and procedure, revised in October 2025, already reflects a more interventionist posture on pre‑notification engagement and information requirements. The CMA’s separate review of merger efficiencies, announced under the 4Ps framework, signals that the regulator intends to move faster and more predictably, but also more assertively where it identifies competition concerns.

Key Takeaways for Sponsors, Lenders and Sellers

• Wider net, faster clock. The consultation proposes changes that industry observers expect will bring more mid‑market transactions within the CMA’s practical reach, even if formal thresholds do not drop dramatically. Pre‑notification diligence is now essential for any PE deal with overlapping UK revenue streams.
• Timing buffers are non‑negotiable. Compressed CMA review windows mean that long‑stop dates, availability periods under facilities and lender consent timetables all need recalibrating.
• Financing documentation must evolve. Standard LMA‑form conditions precedent, material adverse effect (MAE) clauses and drawdown mechanics were not designed for a world in which CMA remedies could materialise faster and earlier in the deal cycle.
• Intercreditor agreements need new provisions. Where CMA remedies may require holdseparate arrangements or partial divestment, waterfall priorities, enforcement standstills and cure periods require explicit merger‑control language.
• Act now, not when legislation passes. The CMA’s guidance changes are already in force; the practical effects of the consultation are being felt in CMA case‑handling today. Deal teams should update templates and processes immediately.

Background: What the Government and CMA Have Proposed and Recent Procedural Changes

Understanding the UK merger control reforms 2026 requires distinguishing between two parallel but related workstreams: the government’s legislative consultation and the CMA’s own operational changes. Both are relevant to private equity merger control in the UK, and both are already influencing CMA case‑handling practice.

The DBT consultation Refining our competition regime, launched on 20 January 2026, covers a broad agenda. Key proposals relevant to M&A include refining the jurisdictional tests that determine whether the CMA can review a transaction, accelerating Phase 1 and Phase 2 timetables, and adjusting the remedies framework to make undertakings in lieu (UILs) and divestment orders more streamlined. The consultation also signals interest in aligning UK merger control more closely with international best practice, a point noted by market commentators at CMS and Slaughter and May as potentially expanding the range of transactions that the CMA can and will review.

The CMA, for its part, has not waited for legislative change. Its October 2025 revision of Mergers: Guidance on the CMA’s jurisdiction and procedure introduced updated expectations for pre‑notification engagement, clearer information‑request standards and a more structured approach to Phase 1 case management. The CMA’s separate announcement of a review of its approach to merger efficiencies, framed within the 4Ps strategy, indicates that the regulator is seeking to demonstrate that it can support pro‑competitive mergers while maintaining rigorous scrutiny of those that raise concerns.

Timeline of Key Dates

Why Private‑Equity and Mid‑Market Deals Are in Focus, CMA Priorities and Risk Indicators

The question of whether the CMA will scrutinise private equity and mid‑market deals more closely after the UK merger control reforms 2026 is already being answered in practice. Market commentary from leading firms, including White & Case and Cooley, highlights that the CMA’s 4Ps agenda, combined with increased analytical resources, is broadening the regulator’s field of view beyond large public‑to‑public transactions. For PE sponsors executing buy‑and‑build strategies, add‑on acquisitions and vertical integration plays, the implications are significant.

Several political and institutional drivers underpin this shift. The government’s consultation explicitly acknowledges the need for a merger regime that supports economic growth while protecting consumers and market competition. The CMA’s strategic steer emphasises that its merger work should be proportionate but comprehensive, and that includes scrutinising transactions where competition effects may be localised or where market definition is evolving. PE‑backed deals often present precisely these characteristics: portfolio roll‑ups that may not individually breach turnover thresholds but collectively transform competitive dynamics in a sector; vertical integrations that create supply‑chain dependencies; and minority stakes that confer material influence without full control.

Typical PE Deal Features That Increase Reportability

Sponsors should be alert to specific transaction characteristics that elevate CMA risk. Buy‑and‑build strategies in fragmented sectors (healthcare, veterinary services, waste management, professional services) are known CMA interest areas. Add‑on acquisitions where the platform company already holds a meaningful share of supply in any local or national market will almost certainly trigger pre‑notification scrutiny. Vendor roll‑ups, where several businesses are acquired simultaneously or in rapid sequence, raise cumulative share‑of‑supply questions even where each individual transaction falls below formal thresholds.

Red Flags in Deal Data Rooms and IMs

The UK Private Capital industry body has flagged these concerns in its April 2026 policy update, noting that sponsors are increasingly encountering CMA interest at earlier stages of the deal cycle. Early indications suggest that the CMA’s enhanced pre‑notification process, formalised in the October 2025 guidance, is being used as a tool to identify potentially problematic PE deals before completion, rather than relying solely on post‑closing investigation.

Practical Implications for Deal Timing, Notification and Closing Mechanics

For deal teams working on UK M&A in 2026, the CMA merger control reforms have immediate practical consequences for transaction timetables, completion conditions and the mechanics that connect signing to closing. The traditional approach, complete the acquisition, then deal with any CMA inquiry post‑closing, carries significantly higher risk in the current environment.

Pre‑Notification Diligence and the “No‑Surprises” Strategy

Under the CMA’s revised guidance, pre‑notification engagement is now a structured process with defined expectations for the information that parties should provide. The CMA has made clear that it expects merging parties to engage early where there is any reasonable prospect of a jurisdictional nexus. For private equity sponsors, this means that competition diligence should begin at or before letter‑of‑intent stage, not as an afterthought once the SPA is signed.

A “no‑surprises” approach involves three elements: mapping all plausible overlaps (horizontal, vertical and conglomerate) using detailed market‑share data; preparing a preliminary self‑assessment of whether the share‑of‑supply or turnover tests are met; and, where the answer is uncertain, engaging directly with the CMA’s mergers unit before signing. This approach does not guarantee a smooth process, but it substantially reduces the risk of a Phase 1 investigation that derails deal timetables and financing availability.

Drafting Completion Mechanics, Conditionality vs Post‑Closing Remedies

The choice between suspensive conditions (where completion is conditional on CMA clearance) and post‑closing remedies (where the deal completes and any CMA issues are dealt with afterwards) is the single most consequential structuring decision in CMA‑sensitive PE deals. The likely practical effect of the 2026 reforms will be to tilt the balance further toward suspensive conditionality for a wider range of transactions.

Where CMA clearance is a condition precedent to completion, deal teams must build sufficient time into long‑stop dates to accommodate Phase 1 review and, in worst‑case scenarios, Phase 2 investigation. Where the parties choose to complete without CMA clearance, they must accept the risk that the CMA could subsequently require divestment or impose holdseparate obligations, a risk that has direct implications for debt financing and intercreditor arrangements.

Financing and Intercreditor Implications, What Lenders Must Change Under the UK Merger Control Reforms 2026

The merger control implications for lenders are among the least discussed but most practically significant consequences of the 2026 reform agenda. Facility agreements, intercreditor arrangements and security documentation all require attention where a transaction carries CMA risk. Deal financing under CMA scrutiny demands a fundamentally different approach to conditionality, drawdown mechanics and covenant design.

Practical Lender Checklist

• Pre‑notification covenant. Include an express covenant requiring the borrower to notify the lender immediately upon becoming aware of any CMA inquiry, request for information or investigation. Standard LMA‑form information covenants are unlikely to capture this adequately.
• Conditions precedent to drawdown. Where CMA risk exists, consider adding CMA clearance (or confirmation that no Phase 1 investigation has been opened) as a condition precedent to initial drawdown or, at minimum, to the release of acquisition‑purpose tranches.
• MAE / MAC clause drafting. Ensure that the material adverse effect definition expressly addresses regulatory intervention by the CMA, including Phase 1 decisions, Phase 2 references, interim orders and remedies. Consider whether a CMA Phase 2 reference should constitute a “stop the world” event entitling the lender to decline further advances.
• Disposal and holdseparate powers. Where CMA remedies may require divestment of part of the acquired business, the facility agreement should contain pre‑agreed mechanics for mandatory prepayment or reallocation of security, and the intercreditor agreement should address the priority of disposal proceeds.
• Escrow and holdback structures. For transactions where completion occurs before CMA clearance, consider requiring a portion of the acquisition facility to be held in escrow pending regulatory outcome, with clear release triggers and a fallback to prepayment if divestment is ordered.

Intercreditor Drafting: Waterfall, Enforcement Standstills, Cure Periods and Consent Thresholds

Intercreditor arrangements in the UK, whether governed by LMA‑standard intercreditor agreements or bespoke documentation, must now account for the possibility that CMA‑ordered remedies could disrupt the expected asset perimeter and cash‑flow profile of the borrower group. Specific drafting points include the following.

Waterfall provisions should expressly address how proceeds from a CMA‑ordered divestment are allocated between senior, mezzanine and other creditor classes. Enforcement standstills should be extended or modified to prevent acceleration of debt during the period between a CMA Phase 2 reference and the final remedies decision. Cure periods for covenant breaches triggered by CMA‑related disruptions (loss of revenue from holdseparate targets, increased costs of compliance with interim orders) should be agreed in advance. Consent thresholds for disposals required by CMA remedies should be set lower than standard disposal consent thresholds to avoid the borrower being trapped between a regulatory obligation to divest and a lender refusal to consent.

Sale Documentation and Sponsor Protections

Share purchase agreements and related transaction documents for private equity deals in the UK must now be drafted with the UK merger control reforms 2026 firmly in mind. Sellers, buyers and their respective counsel need to allocate CMA risk explicitly rather than relying on boilerplate provisions that were designed for a less interventionist regulatory environment.

Break Fee and Reverse Break Fee Drafting Under Higher CMA Risk

Where CMA clearance is a condition to completion, the risk that the condition is not satisfied, or that the CMA imposes unacceptable remedies, must be priced into the deal through break fee and reverse break fee mechanisms. Reverse break fees payable by the buyer to the seller in the event of a CMA prohibition or unacceptable Phase 2 outcome have become increasingly common in UK private equity transactions. Industry observers expect that the 2026 reforms, by increasing the perceived likelihood and speed of CMA intervention, will make reverse break fees a standard feature of mid‑market PE deals rather than a feature reserved for large or obviously problematic transactions.

Practical drafting considerations include setting the reverse break fee at a level that genuinely compensates the seller for the opportunity cost of a failed sale (typically 3–10% of enterprise value, depending on the perceived level of CMA risk); defining the trigger events precisely (CMA prohibition, Phase 2 reference without acceptable UILs, or lapse of the long‑stop date attributable to CMA process); and ensuring that the reverse break fee obligation survives termination of the SPA.

Negotiating Conditionality: Recommended Language and Deal Points

Below are indicative drafting headings and notes, not full legal clauses, that deal teams should consider incorporating into CMA‑sensitive SPAs:

• CMA Clearance Condition. “Completion shall be conditional upon the CMA confirming that it does not intend to refer the Transaction to a Phase 2 investigation, or upon the acceptance by the CMA of undertakings in lieu of such reference on terms reasonably acceptable to the Buyer.” Drafting note: define “reasonably acceptable” by reference to a maximum divestment threshold, e.g., no more than 15% of acquired revenue.
• Long‑Stop Date. Set at a minimum of 6 months post‑signing for deals with moderate CMA risk; 12 months where Phase 2 is a realistic possibility. Include an automatic extension mechanism of 3 months if a Phase 2 reference is made within the original long‑stop period.
• Cooperation Covenant. Both parties to use reasonable endeavours to obtain CMA clearance, including responding to information requests within specified timeframes, offering remedies within agreed parameters and not withdrawing or materially amending the notification without the other party’s consent.
• Antitrust Representations and Warranties. Seller to warrant the accuracy and completeness of all information provided to the CMA. Buyer to warrant that its existing portfolio holdings have been fully disclosed. Include specific indemnities for losses arising from inaccurate competition filings.
• Escrow Provisions. Where completion occurs before CMA clearance, a portion of the purchase price (typically 10–20%) to be held in escrow with jointly instructed escrow agents, released upon CMA clearance or applied toward purchase price adjustment in the event of a CMA‑ordered divestment.

Mitigation Playbook and Recommended Process Map

Navigating private equity merger control in the UK under the 2026 reform agenda requires a structured, proactive approach. The following playbook provides a step‑by‑step framework from letter of intent through to post‑closing remedies management.

10‑Point Checklist

1. Pre‑LOI competition screen. Before signing a letter of intent, commission a preliminary competition assessment mapping all horizontal, vertical and conglomerate overlaps between the target, the acquirer’s existing portfolio and any co‑investment vehicles.
2. Engage regulatory counsel at heads‑of‑terms stage. Do not wait for the SPA. Regulatory counsel should be instructed before exclusivity is granted to assess CMA jurisdiction and notification strategy.
3. Prepare CMA risk matrix for lenders. Provide financing banks with a clear, honest assessment of CMA risk, including likelihood of Phase 1 review, Phase 2 reference and potential remedies, at the earliest stage of the financing process.
4. Build CMA timing into the deal timetable. Model three scenarios: no CMA engagement, Phase 1 review only, and Phase 2 reference. Set the long‑stop date to accommodate the worst‑case scenario with a buffer.
5. Draft conditionality and break fee provisions early. Agree CMA conditionality mechanics and reverse break fee quantum during heads‑of‑terms negotiation, not during SPA drafting under time pressure.
6. Align financing documentation with CMA timetable. Ensure that availability periods, conditions precedent and drawdown mechanics in the facility agreement are consistent with the CMA review timetable modelled in the deal timetable.
7. Negotiate intercreditor protections upfront. Address CMA‑specific intercreditor provisions, enforcement standstills, disposal consent thresholds, covenant holiday triggers, during the initial financing negotiation.
8. Prepare pre‑notification materials in parallel with SPA negotiation. Draft the CMA Merger Notice, supporting market‑share analysis and competitive assessment concurrently with the transaction documents to avoid delay between signing and notification.
9. Establish lender communication protocol. Agree a defined protocol for updating lenders on CMA developments, including triggers for formal lender consent requests and procedures for lender group decisions on CMA‑related amendments or waivers.
10. Plan contingency funding. Identify contingency funding sources (bridge facilities, sponsor equity top‑ups, escrow reserves) to cover the cost of CMA remedies, holdseparate management and any purchase price adjustments resulting from CMA‑ordered divestments.

When to Engage Regulatory Counsel and When to Notify the CMA

Regulatory counsel should be engaged no later than the heads‑of‑terms stage for any PE acquisition where the target has UK revenues exceeding £10 million or where the combined share of supply in any defined market could plausibly exceed 25%. Notification to the CMA remains formally voluntary in the UK, but the practical consequences of failing to notify a transaction that the CMA subsequently investigates, including the risk of interim orders and the reputational cost of a post‑closing unwind, are severe enough that voluntary notification should be the default position for any deal that falls within the CMA’s jurisdictional scope.

When to pause a deal, three concrete triggers:

• CMA issues an initial enforcement order (IEO). If the CMA issues an IEO before or immediately after completion, the deal should be paused and no further integration steps taken until the IEO is lifted or varied. Proceeding in breach of an IEO carries criminal and civil penalties.
• Phase 2 reference is made and financing conditionality is not in place. If a Phase 2 reference is made and the facility agreement does not contain adequate CMA‑specific protections, the lender group is likely to invoke MAE or events‑of‑default provisions. Better to pause and renegotiate than to face acceleration.
• CMA indicates that behavioural or structural remedies will be required that would eliminate more than 25% of the target’s revenue or EBITDA. At this threshold, the transaction economics are fundamentally altered, and sponsors should reassess whether to proceed, renegotiate pricing, or exercise termination rights.

Current Position vs Proposed 2026 Reforms, Comparison for PE Sponsors and Lenders

Conclusion, Immediate Next Steps Under the UK Merger Control Reforms 2026

The UK merger control reforms 2026, driven by both the DBT consultation and the CMA’s own procedural evolution, represent the most significant change to the UK M&A regulatory environment in over a decade. For private equity sponsors, lenders and their advisers, the time to act is now, not when legislation is enacted.

In the first 30 days, deal teams should audit all live and pipeline transactions for CMA risk exposure and update template SPAs, facility agreements and intercreditor agreements with the provisions outlined in this guide. By 60 days, sponsors should have established a relationship with regulatory counsel capable of managing pre‑notification engagement with the CMA on current and anticipated deals. By 90 days, lender groups should have agreed CMA‑specific amendment protocols for existing facilities and embedded merger‑control risk assessment into their standard credit approval processes for new PE‑backed lending.

The reforms are designed to make UK merger control faster and more predictable, but speed and predictability are only advantages for those who are prepared. Parties that embed CMA risk management into their deal processes from the outset will be best positioned to execute transactions efficiently in this new environment.